acquisition of a majority stake in ATI Physical Therapy Holdings, LLC, a provider of outpatient rehabilitation services, including physical therapy and work conditioning, from KRG Capital Partners.
as a member of a consortium, in the consortium’s approximately $3.3 billion take-private of Wuxi PharmaTech, a global contract R&D services provider serving the pharmaceutical and biotechnology industries.
- $5.4 billion acquisition of the animal health business of Novartis AG.
- $960 million acquisition of CoLucid Pharmaceuticals, Inc.
- $410 million sale of veterinary assets to Virbac SA.
- acquisition by Elanco, its animal health division, of Lohmann SE, a supplier of poultry vaccines and feed additives.
$7.6 billion sale to Community Health Systems, Inc.
$17.6 billion all-stock merger of equals with Quintiles Transnational Holdings Inc.
$4.6 billion merger with INC Research Holdings, Inc.
and its portfolio company National Surgical Healthcare in its $760 million sale to Surgery Partners, Inc.
$2.6 billion sale to Valeant Pharmaceuticals International. We also advised on all of the antitrust-related aspects of the acquisition. Weil’s representation of Medicis in the Valeant deal was featured in Law360’s “Sealing the Deal,” which describes the extraordinary 10-day turnaround of the deal. “Having past experience with Medicis gave the attorneys important insight into the company’s sticking points and interests. A deep familiarity with the company’s priorities meant [Matthew] Gilroy had an edge in negotiating the deal quickly: he knew where his focus should be, what to compromise and what to decide.”
€1.8 billion sale of its majority stake in Cerba HealthCare (f/k/a Cerba European Lab) to Partners Group and Public Sector Pension Investment Board.
- acquisition of Aegerion Pharmaceuticals, Inc.
- minority investment in Aralez Pharmaceuticals Plc and distribution of the acquired Aralez shares to its shareholders.
- $25 billion exchange of Merial, its animal health business, for the consumer healthcare business of Boehringer Ingelheim GmbH.
- $20.1 billion takeover of Genzyme, a biotechnology firm.
- in, together with Third Rock Ventures and Greylock Partners, its investment in Warp Drive Bio, a start-up focusing on proprietary genomic technology to discover drugs of natural origin.
- worldwide exclusive licensing agreement with MannKind Corporation to develop and commercialize Afrezza® (insulin human) Inhalation Powder.
- antitrust matters concerning its proposed $66 billion acquisition of Allergan, Inc., a multi-specialty health care company that develops and commercializes pharmaceutical, biological, medical device and over-the-counter products.
- antitrust matters concerning its proposed $600 million sale of the rights to several branded respiratory products in the United States and Canada to AstraZeneca plc.
- Forest Laboratories in antitrust matters related to its $24.2 billion sale to Actavis.
antitrust aspects concerning its $13.4 billion sale to Zimmer Holdings, Inc., a manufacturer of orthopedic reconstructive, dental and spinal implants, and trauma and related surgical products.
- antitrust aspects of its proposed $1.99 billion sale of its Cordis business, a developer and manufacturer of interventional vascular technology, to Cardinal Health, Inc., a provider of pharmaceutical and medical products and services.
- antitrust aspects of its $21.3 billion purchase of Swiss-American orthopedic devices maker Synthes Inc. Weil negotiated a limited divestiture in order to obtain antitrust clearance.
- antitrust aspects of its sale of a majority interest in Walgreens Infusion Services, a major provider of home and alternate treatment site infusion services, to Madison Dearborn Partners.
- antitrust matters with respect to its $6.7 billion acquisition of a 45% interest in Alliance Boots, a Switzerland-based international pharmacy-led health and beauty group. Weil obtained antitrust clearance for the transaction within the initial waiting period, avoiding the potential delay associated with a full-phase investigation.